Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., March 11, 2025 /PRNewswire/ — Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic…
